Stanoeva, K., Fukuda, A., Kawanami, Y, Kuwata, T., Satou, Y., Matsushita, S.: Levels of integrated proviral HIV-1 DNA load in Japanese patients on long-term ART. 16th Kumamoto AIDS Seminar. October 7-9, 2015. Kumamoto.

Maruta, Y., Kuwata, T., Tanaka, K., Ramirez, K., Alam, M., Egami, Y., Suwa, Y., Morioka, H., Matsushita, S.: Post-attachment neutralization by single-chain variable fragments targeting the V3 loop of HIV-1 envelope. 16th Kumamoto AIDS Seminar. October 7-9, 2015. Kumamoto.

Alam, M., Kuwata, T., Maruta, Y., Ramirez K., Tanaka, K., Shimura, K., Oishi, S., Fujii, N., Matsuoka, M., Matsushita, S.: HIV-1 gp41 mutations against fusion inhibitor C34 showed enhanced sensitivity to neutralizing antibodies. 16th Kumamoto AIDS Seminar. October 7-9, 2015. Kumamoto.

Tanaka, K., Kuwata, T., Maruta, Y., Ramirez K., Alam, M., Kawanami, Y., Matsushita S.: Enhanced neutralization of HIV-1 primary isolates by the small antibody fragments targeting CD4-induced (CD4i) epitope. 16th Kumamoto AIDS Seminar. October 7-9, 2015. Kumamoto.

Alves, G., Kuwata T., Tanaka Y., Ariumi, Y., Maruta, Y., Tanaka, K., Alam, M., Stanoeva, K., Hirata, I., Matsushita, S.: Constitutive expression of anti-HIV-1 scFv intrabodies transduced by an HIV-1-based Lentivirus vector. 16th Kumamoto AIDS Seminar. October 7-9, 2015. Kumamoto.

Hirata, I., Kuwata, T., Maruta, Y., Tanaka, K., Alam, M., Matsushita, S.: Epitope analysis of anti-V3 monoclonal antibodies using phage display library. 16th Kumamoto AIDS Seminar. October 7-9, 2015. Kumamoto.

Kuwata, T., Shimizu, M., Matsushita, S. Impact of gp41 mutations for escape from a broad neutralizing antibody against SIV. 16th Kumamoto AIDS Seminar. October 7-9, 2015. Kumamoto.

Tanaka, K., Kuwata, T., Maruta, Y., Ramirez, K., Alam, M., Egami, Ikumi Y., Enomoto, I., Kawanami, Y., Matsushita. S. Potent and broad neutralizing activity of small antibody fragments targeting CD4i (CD4-induced) epitope. The 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) the Vancouver 19-22 July 2015. Vancouver, Canada.

Muntasir, A., Kuwata, T., Ramirez, K., Maruta, Y., Tanaka K., Shimura, K., Oishi, S., Fujii, N., Matsuoka, M., Matsushita, S. Enhanced Neutralization of HIV-1 with Fusion Inhibitor Resistant Mutations. The annual Conference on Retroviruses and Opportunistic Infections (CROI 2015). February 23-26, 2015. Seattle, Washington, USA

Matsushita, S., Ramirez, K.P., Maruta, Y., Tanaka, K., Muntasir, A., Kuwata, T., Pisupait, J., Murakami, T., Yoshimura, K. Therapeutic application of neutralizing antibodies based on the recent data on complementary and synergistic activities against a wide range of HIV-1 strains. the 17th International Conference on Emerging Infectious Diseases (EID) Emerging Infectious Diseases Meeting Jan. 26-27, 2015. Taipei, Taiwan

Maruta, Y ., Kuwata, T., Tanaka, K ., Nakahara, Y ., Ramirez, K., Muntasir, A., Egami, Y., Hirata, I., Suwa, Y ., Morioka, H., Matsushita, S. Post-attachment Neutralization by Single-chain Variable Fragment (scFv) from an Anti-V3 Monoclonal Antibody with Cross-reactivity. Korea-Japan Joint Seminar on HIV/AIDS. January 10, 2015. Kumamoto.

Kuwata, T., Yoshimura, K., Wu, F., Ourmanov, I., Hirsch, V.M., Yokoyama, M., Sato H., and Matsushita, S.　　Mutations in gp41 is Critical to Escape from B404, a Broad Neutralizing Antibody Against SIV, Which Recognizes a V3/V4 Conformational Epitope. 32nd Annual Symposium on Nonhuman Primate Models for AIDS. November 11 – 14, 2014. Portland, Oregon, USA.

Maruta, Y., Kuwata, T., Tanaka K., Nakahara,Y., Ramirez, K., Alam, M., Egami, Y., Hirata I., Suwa, Y., Morioka, H., Matsushita, S. Mechanism of post-attachment neutralization of single-chain variable fragment (scFv) from anti-V3 monoclonal antibody against HIV-1.　 HIV R4P 2014 .　 October 28-31,2014. Cape Town, South Africa.　

Matsushita, S., Ramirez, K.P., Maruta, Y., Tanaka, K., Muntasir, A., Kuwata, T., Pisupait, J., Murakami, T., Yoshimura, K. Therapeutic application of neutralizing antibodies based on the recent data on complementary and synergistic activities against a wide range of HIV-1 strains. 15th Kumamoto AIDS Seminar. October 1-3, 2014. Kumamoto.

Kuwata, T., Enomoto, I., Baba, M., Matsushita, S. Acquisition of resistance to the CCR5 antagonist cenicriviroc renders HIV-1 sensitive to neutralizing antibodies. 15th Kumamoto AIDS Seminar. October 1-3, 2014. Kumamoto.

Ramirez, K.P., Kuwata, T., Maruta, Y, Tanaka K., Muntasir, A., Yoshimura, K., Matsushita, S. Evaluation of complementarity and synergy of conventional anti-HIV-1 antibodies derived from a single individual, 15th Kumamoto AIDS Seminar. October 1-3, 2014. Kumamoto.

Muntasir, A., Kuwata, T., Ramirez, K., Enomoto, I., Maruta, Y., Tanaka K., Rahman K., Nakahara,Y., Egami, Y., Kawanami, Y., Murayama, H., Shimura, K., Matsuoka, M., Matsushita, S. Mutations in gp41 that confer resistance to fusion inhibitors enhance the neutralization sensitivity to antibodies against both gp41 and gp120. 15th Kumamoto AIDS Seminar. October 1-3, 2014. Kumamoto.

Maruta, Y., Kuwata, T., Tanaka K., Nakahara,Y., Ramirez, K., Alam, M., Egami, Y., Hirata I., Suwa, Y., Morioka, H., Matsushita, S. Mechanism of post-attachment neutralization of single-chain variable fragment (scFv) from anti-V3 monoclonal antibody against HIV-1. 15th Kumamoto AIDS Seminar. October 1-3, 2014. Kumamoto.

Tanaka K., Kuwata, T., Maruta, Y., Ramirez, K., Muntasir, A., Egami, Y., Enomoto, I., Kawanami, Y., Matsushita, S. Construction of neutralizing antibody fragment against V3 with a broad cross-reactivity. 15th Kumamoto AIDS Seminar. October 1-3, 2014. Kumamoto.

Boonchawalit, S., Harasda, S., Matsushita, S., Yoshimura, K.: Impact of Maraviroc (MCV)-resistant mutations in C1 and C4 regions of gp120 on sensitivity to antibody-mediated neutralization. 20th International AIDS Conference. Melbourne, Australia. July 20-25,2014.

Alam M, Kuwata T, Ramirez K, Enomoto I, Maruta Y, Tanaka K, Rahman K, Egami Y, Kawanami Y, Murayama H, Shimura K, Matsuoka M, Matsushita S.　Effects of Enfuvirtide resistant mutations on the sensitivity to neutralizing antibodies. 14th Kumamoto AIDS Seminar. 29-31 October 2013, Kumamoto.

Maruta Y, Kuwata T, Tanaka K, Nakahara Y, Ramirez K, Alam M, Egami Y, Suwa Y, Morioka H, Matsushita S. Post-attachment neutralization as a mechanism of efficient activities of scFv from anti-V3 monoclonal antibody. 14th Kumamoto AIDS Seminar. 29-31 October 2013, Kumamoto.

Tanaka K, Kuwata T, Maruta Y, Ramirez K, Kawanami Y, Enomoto I, Matsushita S. Miniaturization of antibodies against CD4-induced epitope on gp120. 14th Kumamoto AIDS Seminar. 29-31 October 2013, Kumamoto.

Ramirez K, Kuwata T, Maruta Y, Tanaka K, Alam M, Rahman K, Egami Y, Kawanami Y, Enomoto I, Tamamura H, Yoshimura K, Matsushita S.　Can antibodies contribute to controlling infection with transmitted/founder virus? 14th Kumamoto AIDS Seminar.　 29-31 October 2013, Kumamoto.

Kuwata T, Takaki K, Yoshimura K, Enomoto I, Wu F, Ourmanov I, Hirsch VM, Yokoyama M, Sato H, Matsushita S. Identification of the Env region responsible for the resistance to B404, a potent neutralizing antibody against SIV. 14th Kumamoto AIDS Seminar. 29-31 October 2013, Kumamoto.

Ramirez K, Kuwata T, Maruta Y, Tanaka K, Alam M, Rahman K, Kawanami Y, Enomoto I, Tamamura H, Yoshimura K, Matsushita S.　Improving the brodality and potency of neutralizing anti-HIV-1 antibodies with a CD4 mimetic compound. AIDS Vaccine 2013. 7-10 October 2013. Barcelona, Spain.

Kuwata T, Takaki K, Yoshimura K, Enomoto I, Wu F, Ourmanov I, Hirsch VM, Yokoyama M, Sato H, Matsushita S.　Analysis of Env regions important for binding and resistance to B404, a potent neutralizing antibody against SIV. AIDS Vaccine 2013. 7-10 October 2013. Barcelona, Spain.

Matsushita S., Yoshimura K., Maeda T., Murakami T., KD-1002 Principal Investigators and The Protocol Team of Quintiles.  Passive transfer of neutralizing monoclonal antibody KD-247 reduces plasma viral load in patientschronically infected with HIV-1: a phase-1b clinical study of a humanized monoclonal antibody KD-247 (KD-1002). 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) , 30 June –3 July 2013 , Kuala Lumpur.

Matsushita S., Yoshimura K., Maeda T., Murakami T., KD-1002 Principal Investigators and The Protocol Team of Quintiles. Passive transfer of neutralizing monoclonal antibody KD-247 reduces plasma viral load in patientschronically infected with HIV-1: a phase-1b clinical study of a humanized monoclonal antibody KD-247 (KD-1002).

Matsushita S.  Passive transfer of neutralizing monoclonal antibody KD-247 reduces plasma viral load in patients chronically infected with HIV-1：A Phase-1b clinical study of a humanized monoclonal antibody KD-247 (KD-1002).  IAS Towards an HIV Cure Symposium. 29-30 June 2013 , Kuala Lumpur.

Sonoda T., Boonchawalit S., Gatanaga H., Tanaka K., Maruta Y., Ramirez K., Kuwata T., Matsushita S.:Cross subtype neutralizing activity of plasma antibodies from patients infected with HIV-1 CRF01_AE HIV-1. 13th Kumamoto AIDS Seminar GCOE Joint International Symposium, 2012.10.25-26, Aso, Kumamoto.

Ramirez K,  Kuwata T., Maruta Y., Tanaka K., Matsushita S.: Sonoda, T, Kawanami Y, Takaki K, Enomoto I. Efficient isolation of monoclonal antibodies against HIV-1from HIV-1 infected patients.  13th Kumamoto AIDS Seminar GCOE Joint International Symposium, 2012.10.25-26, Aso, Kumamoto.

Tanaka K., Kuwata T., Maruta Y., Ramirez K., Matsushita S.: Analysis of antibodies to CD4-induced epitope on gp120. 13th Kumamoto AIDS Seminar GCOE Joint International Symposium, 2012.10.25-26, Aso, Kumamoto.

Maruta Y., Ramirez K., Kuwata T., Suwa Y., Morioka H., Kuwata T, Matsushita S.: Single-chain variable fragment (scFv) of anti-V3 monoclonal antibody efficiently neutralizes HIV-1 in vitro.  13th Kumamoto AIDS Seminar GCOE Joint International Symposium, 2012.10.25-26, Aso, Kumamoto.

Matsushita S., Ramirez K., Maruta Y., Harada S., Maeda T., Murakami T., Kuwata T., Yoshimura K.: CCR5-inhibitor resistance confers neutralization sensitive phenotype to primary HIV-1 isolates: Implications for the passive immunotherapy of neutralizing antibodies with CCR5 inhibitors. 13th Kumamoto AIDS Seminar GCOE Joint International Symposium, 2012.10.25-26, Aso, Kumamoto

Kuwata T., Takaki K., Enomoto, E., Matsushita S: Conformational epitope inbolving V3 and V4 loops is a major tartget for antibody-mediated neutralization in SIV smH635-infected macaques. 13th Kumamoto AIDS Seminar GCOE Joint International Symposium, 2012.10.25-26, Aso, Kumamoto.

Maruta Y., Ramirez K., Kuwata T.,  Matsushita S. :Construction and characterization of neutralizing antibody fragments for efficient access to V3 epitope.  AIDS Vaccine 2012,  September 9-12, 2012, Boston, USA.

Harada S., Arai H., Narumi T., Tamamura H., Matsushita S., Yoshimura K.  In vitro induction of ten CD4 mimic small compounds, NBD-556 and its analogues, resistant variants using primary R5 HIV-1. XIX International AIDS Conference (AIDS 2012), July 22-27, Washington DC, USA.

Ramirez K., Kuwata T., Yoshimura K., Kawanami Y., Enomoto I., Matsushita S. Isolation of two novel CD4-induced monoclonal antibodies (MAbs) with cross-neutralizing activity against viruses of HIV-1 B and non-B subtypes, Keystone Symposia. (Keystone, USA) Mar. 21-26, 2012.

Arai H., Narumi T.,Yoshimura K.,Harada S., Aikawa H., Nomura W., Matsushita S., Tamamura H. Design, synthesis and biological evaluation of CD4 mimics targeting the interaction with Asp368 and Val430 in gp120. 12th Kumamoto AIDS Seminar GCOE Joint International Symposium, 2011.10.19-21, Aso, Kumamoto, Japan.

Narumi T., Arai H., Ochiai C.,Yoshimura K.,Harada S., Nomura W., Matsushita S., Tamamura H. SAR study of small molecular CD4 mimics targeting the dynamic supramolecular mechanism of HIV entry and their hybrid molecules with CXCR4 antagonist. 12th Kumamoto AIDS Seminar GCOE Joint International Symposium, 2011.10.19-21, Aso, Kumamoto, Japan.

Harada S., Ishikawa T., Hamaji A., Matsushita S.,Yoshimura K.  Impact of raltegravir pressure on the selection of HIV-1 envelope sequences in vitro. 12th Kumamoto AIDS Seminar GCOE Joint International Symposium, 2011.10.19-21, Aso, Kumamoto, Japan.

Yoshimura K., Harada S., Hamji A., Matsushita S. Two-step escape pathway of the HIV-1 primary isolates induced by the in vitro selection of maraviroc. 12th Kumamoto AIDS Seminar GCOE Joint International Symposium, 2011.10.19-21, Aso, Kumamoto, Japan.

Yokoyama M., Naganawa S.,Yoshimura K., Matsushita S., Sato H. V3 region-regulated conformations of HIV-1 gp120 outer domain bring insights into structural mechanisms of immune evasion. International Union of Microbiological Societies 2011 Congress. 2011.9.6-16, Sapporo, Japan.

Yoshimura K.,Harada S.,Hamji A., Matsushita S. Maraviroc-resistant subtype B primary HIV-1 induced in vitro selection became highly sensitive to anti-gp120 neutralizing antibodies and autologous plasma IgG under high concentrations of the CCR5 inhibitor. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 2011.7.17-20, Roma, Italy.

Matsushita, S., Mouri, S., Harada, S., Yamada, Y., Tamamura, H., Yoshimura, K.: Strategy to overcome neutralization resistance of HIV-1 primary isolates.  11th GCOE Joint International Symposium Kumamoto AIDS Seminar Octoer 6-8, 2010. Kumamoto.

Liu, M., Shibata, J., Harada, S., Takehisa, J., Yoshimura, K., Matsushita, S.: Impact of a point mutation V2 (L175P) in neutralization resistance mediated by functional trimer formation of Env. AIDS Vaccine 2010, Sep.28-Oct.1, 2010. Atlanta, USA.

Matsushita, S., Mouri, S., Harada, S., Yamada, Y., Tamamura, H., Yoshimura, K.: CD4 mimetic compound-mediated enhancement of the neutralization activities of anti-V3 and CD4i monoclonal antibodies against the standard panel of primary isolates. XVIII International AIDS Conference. July.18-23, 2010. Vienna, Austria.

Harada S., Yoshimura K., Kawanami Y., Matsushita S. In vitro selections of raltegravir resistant variants using diverse primary isolates, subtype B, C, CRF01_AE, and CRF08_BC. 2010 IYIS, 2010.3.4-5, Kumamoto, Japan.

Yoshimura K., Harada S., Matsushita S. Two step escape pathway of the HIV-1 subtype C primary isolate induced by the in vitro selection of Maraviroc. 17th Conference on Retroviruses and Opportunistic Infections (CROI 2010), 2010.2.16-19, San Francisco, USA.

Narahara C, Hatada M, Harada S., Yoshimura, K,. Matsushita S，: A primary R5 isolate undergoes different escape pathway during in vitro selection with low or high concentration of an anti-V3 monoclonal antibody. AIDS Vaccine 2009, 2009.10.19-22, Paris.

Matsushita S: Accumulation of multiple functional mutations in HIV-1 gp120 is　involved in the development of neutralization escape under pressure of neutralizing antibody in vitro. Kumamoto AIDS Seminar GCOE Joint International Symposium- Satellite Symposium, 2009.9.30, Aso, Kumamoto.

Yoshimura K, Matsushita S: In vitro induction of HIV-1 resistant to a CCR5. Kumamoto AIDS Seminar GCOE Joint International Symposium- Satellite Symposium, 2009.9.30, Aso, Kumamoto

Matsushita S. Narahara C, Nishida Y, Honda A., Harada S., Yoshimura K.: Polyclonal antibody response against gp120 including antibodies to V3, CD4bs and CD4i epitopes account or broad neutralization. 10th Kumamoto AIDS Seminar GCOE Joint International Symposium. 2009.9.28-29, Kumamoto.

Hatada M. Yoshimura K., Harada S, and Matsushita S.:Mechanism of maintaining a glycan-insertion in HIV-1 gp120 V2 region under pressure of a potent neutralizing antibody in vitro. 10th Kumamoto AIDS Seminar GCOE Joint International Symposium. 2009.9.28-29, Kumamoto.

Ishikawa T., Yoshimura K., Hatada M. Harada S, and Matsushita S.: Mutations in gp120 of R5 HIV-1 laboratory isolate induced by the in vitro selection of maraviroc confer highly sensitive to anti-V3 monoclonal antibody. 10th Kumamoto AIDS Seminar GCOE Joint International Symposium. 2009.9.28-29, Kumamoto

Yoshimura K., Harada S, Hatada M. and Matsushita S.: In vitro induction of HIV-1 resistant to a CCR5 antagonist maraviroc. 10th Kumamoto AIDS Seminar GCOE Joint International Symposium. 2009.9.28-29, Kumamoto

Harada S, Yoshimura K., and Matsushita S.: Generation of an integrase inhibitor raltegravir resistant variants using recent primary isolates, X4, R5 and dual/mix HIV-1. 10thKumamoto AIDS Seminar GCOE Joint International Symposium. 2009.9.28-29, Kumamoto

Matsushita S, Narahara C, Morizono M, Nishida Y, Honda-Shibata A, Harada S, Yoshimura K: Polyclonal antibody response against gp120 including antibodies to V3, CD4bs and CD4i eppitopes account or broad neutralizaion. 5th Conference on HIV Pathogenesis, Treatment and prevention. 2009.7.19-22,Cape Town,South Africa

Yoshimura, K, Harada S., Hatada, M., Matsushita S.:Mutations in V4 and C4 regions of the HIV-1 CRF-BC envelope induced by the in vitro selection of Maraviroc Confer cross-resistance to other CCR5 inhibitors. 16th Conference on Trtroviruses and Opportunistic Infections(CROI 2009). 2009 2..8-11, Montreal, Canada

Narahara, C., Yoshimura, K, Hatada, M., Harada ,S., Matsushita, S.: Different mutation in HIV-1 gp120 V3-tip regin for escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection with low or high concentration of the Mab. 9th Kumamoto AIDS Seminar. Sep. 18-19, 2008, Aso, Kumamoto.

Hatada, M., Yoshimura, K, Ishikawa T., Harada S., Matsushita S.: The impact of an N-linked glycosylation site insertion in HIV-1 gp120 region to escape from a potent neutralization anti-V3 monoclonal antibody. 9th Kumamoto AIDS Seminar. Sep. 18-19, 2008, Aso, Kumamoto.

Yoshimura, K, Hatada, M., Harada S., Shibata J., Masuo, H., Tamamura, H., Matsushita S.: In vitro induction of human immunodeficienby virus type 1 variants resistant to a low-molecular CD4 mimic compound. 9th Kumamoto AIDS Seminar. Sep. 18-19, 2008, Aso, Kumamoto

Yoshimura, K, Shibata J., Honda, A., Yamada, Y., Nasuo, H., Tamamura, H., Matsushita S.:In vitro induction of human immunodeficienby virus type 1 variants resistant to a low-molecular CD4 mimic compound, N- (4- Chlorophenyl) -N’ – (2,2,6,6-tetramethylpiperidin- 4-yl) – oxalamide (NBD-556). 15th Conference on Retroviruses and Opportunistic infections. Feb. 3-6, 2008, Boston, USA.

Matsushita S., Nishida, Y., Shibata J., Honda A., Yoshimura, K: Broad cross-neutralization mediated by combination of anti-V3 and CD4 binding site antibodies in an HIV-1 infected patient with long-term non-progressie disease. 15th Conference on Retroviruses and Opportunistic infections. Feb. 3-6, 2008, Boston, USA

Matsushita S.：Development of broadly reactive neutralizing monoclonal antibody KD-247: implications for passive immunotherapy. Tentative Program for the 3rd Japan-Germany HIV/AIDS Symposium. Nov. 26, 2007. Hiroshima.

Yoshimura, K., Shibata, J., Honda A., Tamamura, H., and Matsushita S.: A potent neutralizing anti-V3 monoclonal antibody, KD-247 shows favorable synergism with other antiretrovirals, sCD4 and CD4 mimic small compound in vitro. 8th AIDS Seminar in Kumamoto. Sep 13-14, 2007. Aso, Kumamoto.

Hatada, M., Yoshimura K, Shibata J, Matsushita S. HIV-1BaL mutants escaping neutralization from a potent neutralizing anti-V3 monoclonal antibody KD-247. . 8th AIDS Seminar in Kumamoto. Sep 13-14, 2007. Aso, Kumamoto.

Shibata J, Yoshimura K, Matsushita S. :The single mutation in V2 domain affects quaternary structure of trimer gp120 and dramatically increases the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralizing antibodies. 8th AIDS Seminar in Kumamoto. Sep 13-14, 2007. Aso, Kumamoto.

Nishida,Y., Shibata, J., Yoshimura K., and Matsushita,S.:　Broad neutralization against the HIV-1 subtype B panel of reference strains by　human monoclonal antibodies established from an HIV-1infected long-term non-progressor. 8th AIDS Seminar in Kumamoto. Sep 13-14, 2007. Aso, Kumamoto.

Yoshimura K, Shibata J, Honda A,Koito A, Matsushita S. A potent neutralizing anti-V3 monoclonal antibody, KD-247 shows faborable synergism with other antiretrovirals,sCD4 and CD4 mimic small compound in vitro. The 4th IAS conference on HIV Pathogenesis, Treatment and Prevension, July 22-25, 2007

Matsushita S., Ikeda, T, Shibata J., Honda A., Koito K, Yoshimura. K. Persistence of proviral DNA and the integration sites of HIV-1 in patients on prolonged and effective HAART. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Sydney, Australia. June. 22-25, 2007.

Yoshimura K, Shibata J, Honda A, Koito A, Matsushita S. A novel potent neutralizing anti-V3 monoclonal antibody, KD-247, that shows faborable synergism with anti-CCR5 inhibitors in vitro. 7th AIDS Seminar in Kumamoto, Sep 21-22, 2006.

Shibata J, Yoshimura K, Honda A, Koito A, Murakami T, Matsushita S. Impact of V2 mutations for escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary HIV-1 isolate. 7th AIDS Seminar in Kumamoto, Sep 21-22, 2006

Ikeda T, Shibata J, Yoshimura K, Koito A, Matsushita S. Recurrent HIV-1 integration at BACH2 locus in resting CD4+ T cell populations during effective HAART. 7th AIDS Seminar in Kumamoto, Sep 21-22, 2006.

Matsushita S., Shibata J., Honda A., Murakami T, Eda Y, Koito A, Yoshimura . Development of broadly immunotherapy. AIDS Vaccine 2006 Conference, Amsterdam, the Netherlands, Aug. 29-Sep.1, 2006.

Yoshimura, K., Shibata, J., Honda A., Murakami,T., Mitsuya,H., Koito, A., and Matsushita S.: Resistance Profile of A Novel Broadly Neutralizing Anti-HIV Monoclonal Antibody, KD-247 That Has Favorable Synergism with Anti-CCR5 Inhibitors In Vitro.13th Conference on Retroviruses and Opportunistic Infections. Denver, USA, Feb.4-9, 2006.

Shibata, J., Yoshimura, K., Honda A., Murakami,T., Koito, A., and Matsushita S.: A Role of Mutations in Non-V3 Envelope Regions for Escape from a Broad Neutralizing Anti-V3 Monoclonal Antibody, KD-247, during in vitro Selection. 13th Conference on Retroviruses and Opportunistic Infections. Denver, USA, Feb.4-9, 2006

Matsushita S., Honda A., Shibata, J., Kimura T., Ikeda, T., Koito, A., Yoshimura, K.: HIV-1 proviral DNA dynamics in patients with long-term successful HAART. 2nd International Workshop on HIV Persistence during Therapy. 12. 6-9, 2005, Saint Martin, FWI.

Ikeda, T., Shibata, J., Honda A., Yoshimura K., Koito, A., Matsushita, S.: Relationship of residual HIV-1 and the integration sites in patients on prolonged and effective HAART. International Symposium, The Cooperative research Project on Clinical and Epidemiological Studies of Emerging and Re-emerging Infectious Diseases, 2005. 9.15-16. Kumamoto.

Shibata, J., Yoshimura K., Maeda, Y., Murakami, T., Eda. Y., Koito, A., Matsushita, S.: In vitro induction of human immunodeficiency virus type 1 variants resistant to a novel broad neutralizing anti-HIV monoclonal antibody, KD-247. International Symposium, The Cooperative research Project on Clinical and Epidemiological Studies of Emerging and Re-emerging Infectious Diseases, 2005. 9.15-16. Kumamoto.

Yoshimura K., Shibata, J., Ikeda, T., Honda A., Koito, A., Matsushita, S.: HIV-1 proviral DNA dynamics in patients with long-term successful HAART. International Symposium, The Cooperative research Project on Clinical and Epidemiological Studies of Emerging and Re-emerging Infectious Diseases, 2005. 9.15-16. Kumamoto.

Matsushita S., Shibata, J., Yoshimura, K., Maeda,Y., Murakami,T., Koito A, Honda, M., Mitsuya,H., Eda, Y. : Development of broadly reactive neutralizing monoclonal antibody KD247: implication for passive immunotherapy. The cooperative research project on clinical and epidemiological studies of emerging and re-emerging infectious diseases, Aso, Japan, Sep. 15-16, 2005.

Matsushita, S., Honda A., Kenai, A., Shibata, J., Koito, A., Yoshimura K.: Long-Term Follow-Up Study for the Change of the Reservoir for HIV-1 on Highly Active Antiretroviral Therapy. 7th International Congress on AIDS in Asia and the Pacific. 2005. 7. 1-5. Kobe.

Yoshimura K., Honda A., Kenai, A., Shibata, J., Koito, A., Matsushita, S.: Proviral DNA and Turnover Levels in Aviremic Long-Term Non-Progressors (LTNPs); A Temporary Goal forreactive neutralizing monoclonal antibody KD247: implicat5ions for passivePatients under HAART. 7th International Congress on AIDS in Asia and the Pacific. 2005. 7. 1-5. Kobe.児島.

Matsushita,S.: International symposium of AIDS Research Institute in Yonsei University College of Medicine“HIV/AIDS”. 2004.10.15. Seoul, Korea.

Iwata, R., Shibata, J., Kimura, T., Yoshimura K., Koito, A., Matsushita, S.: Cross neutralizing activity of serum antibodies with neutralizing activity against autologous HIV. 5th AIDS seminar in Kumamoto 2004.9.9-10.Kumamoto.

Shibata, J., Wang, F.X., Kimura, T., Iwata R., Yoshimura K., Koito, A., Matsushita, S.: Involvement of C3 mutation in neutralization sensitivity for anti-V3 antibodies. 5th AIDS seminar in Kumamoto 2004.9.9-10.Kumamoto.

Matsushita, S., Kimura, T., Shirai, N., Koito, A., Yoshimura, K. New approach for optimization of HAART; Evaluation of residual viral replication by monitoring proviral DNA level and T cell turnover rate. XV International AIDS Conference Bangkok, 2004.7.11-16, Bangkok, Thailand.

Kenai, A., Kimura, T., Yoshimura K., Koito, A., Matsushita, S.: Efficient induction of both cellular and humoral immune responss by immuniztion with Tat-Nef fusion protein (tNEF) without adjuvants.　XV International AIDS Conference Bangkok, 2004.7.11-16, Bangkok, Thailand.

Matsushita S., Kimura T., Shirai N., Koito A., Yoshimura K.: Evaluation of residual viral replication for optimization of HAART. 1st International Workshop on HIV Persistence during Therapy. 12.10-12, 2003,Saint Martin, FWI.

Yoshimura K, Kimura T, Matsushita S: Proviral DNA (pDNA) and turn over levels in HIV-1-positive long-term non-progressors (LTNPs). 2003 International Meeting of the Institute ofHuman Virology. 9.29-10.3 2003,Baltimore,U.S.A..

Matsushita S. Status of HIV/AIDS inJapan. International Symposium of the Foundation ofEast Asia Network on HIV. 9.26, 2003,Seoul,Korea.

Matsushita S.: Anti-HIV immunity of patients with long-term viral suppression by HAART. U.S.-Japan Cooperative Medical Science Program 15th Joint Meeting of the AIDS Panels, 3.5-7, 2003,Okinawa.

Kimura T, Yoshimura K, Koito A, Matsushita S: Antibody-mediated neutralization against dual tropic viruses depends on coreceptor usages. XIV International AIDS Conference. 2002.7.7-12,Barcelona,Spain.

Yoshimura K, Wang FX, Kimura T, Koito A, Matsushita S: Detecting the residual replication level to potentiate HAART regimen for a salvage therapy. XIV International AIDS Conference.. 2002.7.7-12,Barcelona,Spain.

Matsushita S, Kimura T, Wang FX, Kim J, Koito A, Yoshimura K: Reconstitution of autologous isolate neutralizing antibody under HAART and emergence of neutralization escape mutants in vivo. XIV International 　AIDS Conference. 2002.7.7-12,Barcelona,Spain.

Matsushita S, Wang FX, Kimura T, Nishihara K,Yoshimura K, Koito A: HIV quasispecies and neutralization escape in vivo. 14th Joint AIDS Panels Meeting,March 19-21, 2002,Seattlle,U.S.A.

Wang FX, Kimura T, Nishihara K, Yoshimura K, Koito A, Matsushita S:Emergence of autologous neutralizaton resistant variants from Pre-existing　quasispecies during viral-rebound of HIV-1 infected patients undergoing HAART. 2nd AIDS Seminor inKumamoto. 9.20-21, 2001.

Koito A., Shigekane H., Matsushita S: Assembly defects of HIV-1 gag in murine cells. 2nd AIDS Seminor in Kumamoto.　 9.20-21 2001.

Wang FX, Kimura T, Nishihara K, Yoshimura K, Koito A, Matsushita S:Emergence of autologous neutralizaton resistant variants from Pre-existing quasispecies during viral-rebound of HIV-1 infected patients under treatment of HAART. 2001 International Meeting of the Institute of Human　Virology. 9.9 -13, 2001.Baltimore, U.S.A